Nicox: 2023 Ordinary Shareholder Meeting
02 Giugno 2023 - 7:30AM
Nicox: 2023 Ordinary Shareholder Meeting
Press Release |
Nicox: 2023 Ordinary Shareholder Meeting |
June
2, 2023 – release at 7:30 am CET Sophia Antipolis,
FranceNicox SA (Euronext Paris: FR0013018124,
ALCOX), an international ophthalmology company, informs its
shareholders that the Ordinary general meeting convened on first
call on Thursday June 1st, 2023, was not held as the quorum
required by law was not reached.The shareholders of Nicox are thus
convened on second call for an Ordinary general meeting on the same
resolutions and the same agenda on Thursday June
15 at 2:00 pm CET in the offices of
BuroClub -
Drakkar 2 -
Bâtiment D - 2405 route des Dolines -
06560 Valbonne Sophia Antipolis -
France.The documents mentioned in articles R.22.10-23 of
the French Code de commerce, including a proxy voting form, are
sent to the shareholders upon written request. These documents are
also made available to shareholders at the headquarters of the
Company and on its website (www.nicox.com).Shareholders may vote by
proxy, by internet or by attending the Ordinary shareholder meeting
in person. A guide explaining how to vote, and notably how to vote
by internet, is posted on Nicox’s website. Shareholders may also
contact the Company’s Investor Relations team at
ag2023nicox@nicox.com for any question on the voting process. The
proxy forms sent by correspondence, or the electronic votes
received for the Ordinary general meeting initially planned on June
1st, 2023 remain valid for the Ordinary general meeting of June 15,
2023. |
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470, a
novel nitric oxide-donating bimatoprost, for lowering intraocular
pressure in patients with open-angle glaucoma or ocular
hypertension. The company is also conducting research on NCX 1728,
a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal
conditions. NCX 4251, a novel, patented, ophthalmic suspension of
fluticasone propionate nanocrystals for topical ocular application
for dry eye disease, is being developed by Ocumension Therapeutics
in China under an exclusive license agreement and is available for
partnering elsewhere. Nicox generates revenue from VYZULTA® in
glaucoma, licensed exclusively worldwide to Bausch + Lomb, and
ZERVIATE® in allergic conjunctivitis, licensed in multiple
geographies, including to Eyevance Pharmaceuticals, LLC (a wholly
owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S.
and Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets. Nicox, headquartered in
Sophia Antipolis, France, is listed on Euronext Growth Paris
(Ticker symbol: ALCOX) and is part of the CAC Healthcare index.For
more information on Nicox, its products or pipeline, please visit:
www.nicox.com. |
Analyst coverage |
Bryan, Garnier & Co
Eric
Yoo Paris,
FranceEdison Investment
Research Pooya
Hemami London,
UKH.C. Wainwright &
Co Yi
Chen New York,
U.S.Kepler
Cheuvreux Arsene
Guekam Paris,
France |
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
Contacts |
|
NicoxGavin SpencerExecutive Vice President, Chief
Business Officer& Head of Corporate Development T +33 (0)4 97
24 53 00communications@nicox.com |
|
Forward-Looking Statements |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.Risks factors which are likely to have a material effect
on Nicox’s business are presented in section 2.7 of the ‘Rapport
Annuel 2022’ which is available on Nicox’s website
(www.nicox.com) |
Nicox S.A.Drakkar 2Bât D, 2405 route des
Dolines06560 Valbonne, FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24
53 99 |
- EN_AGO June 2023_quorum not reached PR_20230602
Grafico Azioni Nicox (LSE:0RCQ)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Nicox (LSE:0RCQ)
Storico
Da Mag 2023 a Mag 2024